Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

BACKGROUND: This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor−related protein (GITR), in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Ben, Carvajal, Richard D., Marabelle, Aurelien, Patel, Sandip Pravin, LoRusso, Patricia M., Rasmussen, Erik, Juan, Gloria, Upreti, Vijay V., Beers, Courtney, Ngarmchamnanrith, Gataree, Schöffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156919/
https://www.ncbi.nlm.nih.gov/pubmed/30253804
http://dx.doi.org/10.1186/s40425-018-0407-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156919/
https://www.ncbi.nlm.nih.gov/pubmed/30253804
http://dx.doi.org/10.1186/s40425-018-0407-x

Ejemplares similares